Novo Nordisk Goes On Offense, Says Its Levemir Insulin Is Safer Bet
This article was originally published in The Pink Sheet Daily
Executive Summary
As news of cancer risk for Lantus sinks in, Novo says it is prepared to pick up orders for patients who want to switch.